Can Psilocybin Help With Treatment-Resistant Depression? COMPASS Pathways Study Shows Promising Results
COMPASS Pathways plc (NASDAQ: CMPS), a mental health care company, presented positive data from the randomized, controlled, double-blind study of psilocybin therapy, at the American Psychiatric Association annual meeting in New Orleans.
